Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Merus N.V. (MRUS : NSDQ)
 
 • Company Description   
Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.

Number of Employees: 260

 
 • Price / Volume Information   
Yesterday's Closing Price: $39.43 Daily Weekly Monthly
20 Day Moving Average: 724,321 shares
Shares Outstanding: 69.18 (millions)
Market Capitalization: $2,727.90 (millions)
Beta: 0.94
52 Week High: $61.61
52 Week Low: $33.19
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.33% -3.42%
12 Week -2.06% 5.26%
Year To Date -6.23% -2.06%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
UPPSALALAAN 17
-
UTRECHT,P7 3584
NLD
ph: 31-85-016-2500
fax: -
s.spear@merus.nl http://www.merus.nl
 
 • General Corporate Information   
Officers
Sven (Bill) Ante Lundberg - President; Chief Executive Officer; Principal Exec
Anand Mehra - Chairman of the Board of Directors
Gregory D. Perry - Chief Financial Officer; Principal Financial Offic
Harry Shuman - Chief Accounting Officer; Principal Accounting Off
Len Kanavy - Director

Peer Information
Merus N.V. (CORR.)
Merus N.V. (RSPI)
Merus N.V. (CGXP)
Merus N.V. (BGEN)
Merus N.V. (GTBP)
Merus N.V. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N5749R100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
Share - Related Items
Shares Outstanding: 69.18
Most Recent Split Date: (:1)
Beta: 0.94
Market Capitalization: $2,727.90 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.16 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.48 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/07/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.17
Price/Cash Flow: -
Price / Sales: 49.84
EPS Growth
vs. Year Ago Period: -137.29%
vs. Previous Quarter: -241.46%
Sales Growth
vs. Year Ago Period: 235.76%
vs. Previous Quarter: 189.80%
ROE
03/31/25 - -34.66
12/31/24 - -29.48
09/30/24 - -38.89
ROA
03/31/25 - -28.86
12/31/24 - -23.91
09/30/24 - -31.16
Current Ratio
03/31/25 - -
12/31/24 - 6.54
09/30/24 - 8.32
Quick Ratio
03/31/25 - -
12/31/24 - 6.54
09/30/24 - 8.32
Operating Margin
03/31/25 - -442.87
12/31/24 - -499.20
09/30/24 - -583.34
Net Margin
03/31/25 - -506.73
12/31/24 - -595.93
09/30/24 - -680.61
Pre-Tax Margin
03/31/25 - -
12/31/24 - -573.37
09/30/24 - -659.93
Book Value
03/31/25 - -
12/31/24 - 9.46
09/30/24 - 10.27
Inventory Turnover
03/31/25 - -
12/31/24 - -
09/30/24 - -
Debt-to-Equity
03/31/25 - -
12/31/24 - 0.00
09/30/24 - 0.00
Debt-to-Capital
03/31/25 - -
12/31/24 - 0.00
09/30/24 - 0.00
 

Powered by Zacks Investment Research ©